ANDA 78804, held by Barr Laboratories. Aspirin; Dipyridamole.
As of Nov 22, 2026, ANDA 78804 (Aspirin and Dipyridamole), held by Barr Laboratories, was first approved by FDA on Aug 14, 2009, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 14, 2009 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Aspirin and Dipyridamole25MG;200MG · capsule, extended release;oral | Aspirin; Dipyridamole | Rx |
| Aug 5, 2022 | Supplement 10Labeling · Standard review | Approved | None posted |
| Feb 27, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 27, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 2, 2018 | Supplement 2Manufacturing | Approved | None posted |
| Aug 14, 2009 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters